|
|
Article: Ore Pharmaceuticals Acquires Repositioned Clinical-Stage Drug Candidate from Roche.
- Article from:
- Clinical Trials Week
- Article date:
- August 18, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Ore Pharmaceuticals Inc. (NASDAQ:ORXE) announced that it has acquired from Roche the clinical-stage compound tiapamil. Ore Pharmaceuticals had previously identified potentially novel therapeutic uses for tiapamil in central nervous system (CNS) disease and recently filed for patent protection regarding the use of the compound. The Company plans to further develop tiapamil, and will select the most appropriate of several potential indications, prepare for Phase II clinical trials, and initiate out-licensing activities (see also Ore Pharmaceuticals Inc.).
Ore Pharmaceuticals analyzed and subsequently acquired the compound as part of the previously announced drug ...